Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00...
-
LONDON, March 27, 2024 (GLOBE NEWSWIRE) -- Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit), and Vayana TradeXchange announce a partnership to use Arqit’s TradeSecure™ digital negotiable instrument...
-
ATLANTA, March 26, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ: CDLX) (“Cardlytics”), an advertising platform in banks’ digital channels, today announced the pricing of its offering of $150.0...
-
SAN ANTONIO, March 26, 2024 (GLOBE NEWSWIRE) -- Der neue KI-Forschungsbericht für das Jahr 2024 von Foundry for AI by Rackspace (FAIR™), der von AWS gesponsert und von Rackspace Technology® (NASDAQ:...
-
LA JOLLA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...
-
NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Verizon customers will soon be able to experience Samsung One UI 6.1 with Galaxy AI2 on additional Samsung smartphones beyond the Galaxy S24 series. This...
-
HENDERSON, Nev., March 26, 2024 (GLOBE NEWSWIRE) -- Movella Holdings Inc. (NASDAQ: MVLA) (“Movella” or the “Company”), a leading full-stack provider of sensors, software, and analytics that enable...
-
NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- AMC Networks Inc. (“AMC Networks” or the “Company”) (Nasdaq: AMCX) today announced that it has priced an offering of $875 million aggregate principal...
-
SAULT STE. MARIE, Ontario, March 26, 2024 (GLOBE NEWSWIRE) -- Algoma Steel Group Inc. (NASDAQ: ASTL; TSX: ASTL) (“Algoma”), a fully integrated producer of hot and cold rolled steel products...
-
Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...